S&P 500
(0.18%) 5 109.28 points
Dow Jones
(0.17%) 38 306 points
Nasdaq
(0.20%) 15 960 points
Oil
(-1.01%) $83.00
Gas
(4.68%) $2.01
Gold
(0.10%) $2 349.50
Silver
(0.12%) $27.57
Platinum
(4.08%) $959.70
USD/EUR
(-0.18%) $0.933
USD/NOK
(-0.27%) $11.00
USD/GBP
(-0.45%) $0.797
USD/RUB
(1.73%) $93.46

リアルタイムの更新: Sanofi SA [SNW.DE]

取引所: XETRA セクター: Pharmaceuticals 産業: Drug Manufacturers—General
最終更新日時30 4月 2024 @ 00:35

0.01% 91.47

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:35):

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
本日の出来高 1 863.00
平均出来高 3 632.00
時価総額 114.46B
EPS €2.55 ( 2023-10-27 )
Last Dividend €3.56 ( 2023-05-30 )
Next Dividend €0 ( N/A )
P/E 25.34
ATR14 €0.149 (0.16%)

ボリューム 相関

長: -0.13 (neutral)
短: -0.43 (neutral)
Signal:(44.681) Neutral

Sanofi SA 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sanofi SA 相関 - 通貨/商品

The country flag 0.53
( weak )
The country flag 0.51
( weak )
The country flag 0.11
( neutral )
The country flag 0.55
( weak )
The country flag -0.65
( weak negative )
The country flag -0.48
( neutral )

Sanofi SA 財務諸表

Annual 2023
収益: €43.07B
総利益: €28.83B (66.95 %)
EPS: €4.31
FY 2023
収益: €43.07B
総利益: €28.83B (66.95 %)
EPS: €4.31
FY 2022
収益: €45.39B
総利益: €31.69B (69.83 %)
EPS: €6.69
FY 2021
収益: €39.18B
総利益: €26.92B (68.72 %)
EPS: €4.96

Financial Reports:

No articles found.

Sanofi SA Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€3.56
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Sanofi SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.67 - Stable (33.31%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €2.07 2008-05-16
Last Dividend €3.56 2023-05-30
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 16 --
Total Paid Out €45.47 --
Avg. Dividend % Per Year 0.00% --
Score 3.29 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 6.67
Div. Directional Score 8.77 --
Next Divdend (Est)
(2025-03-31)
€3.71 Estimate 3.11 %
Dividend Stability
0.25 Very Poor
Dividend Score
3.29
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PUM.DE Ex Dividend Junior 2023-05-25 Annually 0 0.00%
BMW.DE Ex Dividend Junior 2023-05-12 Annually 0 0.00%
INN1.DE Ex Dividend Junior 2023-08-07 Semi-Annually 0 0.00%
SWF.DE Ex Dividend Junior 2023-09-01 Quarterly 0 0.00%
CVS.DE Ex Dividend Knight 2023-10-19 Quarterly 0 0.00%
LUS1.DE Ex Dividend Junior 2023-06-23 Annually 0 0.00%
2M6.DE Ex Dividend Knight 2023-09-21 Quarterly 0 0.00%
VFP.DE Ex Dividend Junior 2023-09-08 Quarterly 0 0.00%
ENI.F Ex Dividend Knight 2023-11-20 Semi-Annually 0 0.00%
NVJP.DE Ex Dividend Knight 2023-08-18 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1391.5007.2310.00[0 - 0.5]
returnOnAssetsTTM0.06271.2007.919.49[0 - 0.3]
returnOnEquityTTM0.1081.5009.9210.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.2770.8008.626.89[1 - 3]
quickRatioTTM0.3900.800-2.41-1.928[0.8 - 2.5]
cashRatioTTM0.3631.5009.1010.00[0.2 - 2]
debtRatioTTM0.132-1.5007.80-10.00[0 - 0.6]
interestCoverageTTM7.431.0008.368.36[3 - 30]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
freeCashFlowPerShareTTM5.602.007.2010.00[0 - 20]
debtEquityRatioTTM0.225-1.5009.10-10.00[0 - 2.5]
grossProfitMarginTTM0.6781.0002.032.03[0.2 - 0.8]
operatingProfitMarginTTM0.2311.0007.397.39[0.1 - 0.6]
cashFlowToDebtRatioTTM0.6151.0007.697.69[0.2 - 2]
assetTurnoverTTM0.4520.800-0.318-0.255[0.5 - 2]
Total Score10.87

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM14.441.0008.640[1 - 100]
returnOnEquityTTM0.1082.509.9510.00[0.1 - 1.5]
freeCashFlowPerShareTTM5.602.008.1310.00[0 - 30]
dividendYielPercentageTTM3.891.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM8.202.007.2710.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.6591.5008.940[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1801.0008.010[0.1 - 0.5]
Total Score6.67

Sanofi SA

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。